This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AMRI Promotes Daniel Conlon To Senior Director Of Business Development

ALBANY, N.Y., Sept. 10, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Daniel Conlon has been promoted to Senior Director, Business Development, AMRI, reporting to Christopher Conway, Vice President, Business Development, North America.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

In this newly created role, Conlon will lead AMRI's development and manufacturing services sales team for North America. His responsibilities will include assisting with the strategic direction for generating sales in the North American territory and with the execution of revenue goals for his team.

"Dan is a leader in the truest sense of the word," Mr. Conway says. "He has the proven ability to energize a team while setting the highest attainable standards. Dan's sales and management experience makes him ideal for this position."

Conlon's demonstrated knowledge and ability to sell AMRI's development and manufacturing services earned him the top sales position in 2012. Before joining AMRI in 2010, Conlon held a sales and management position with Merck, formally Organon BioSciences. He worked for Merck/Organon for eight years starting as a Sales Representative/District Trainer. Following this role, he was promoted to District Sales Manager overseeing a team across multistate districts.

"The strengthening of our Business Development team will help us build upon an already solid foundation for growth and will further enhance AMRI's strategic SMARTSOURCING™ approach," said Thomas D'Ambra, Ph.D., AMRI's Chairman, President and Chief Executive Officer. "We are very encouraged by the talented and motivated people on our team, and the prospects for continued growth in the future."

About AMRIAlbany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For press releases and additional information about the company, please visit www.amriglobal.com.

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs